← Compound Library

Desmopressin

Vasopressin Analog (V2 selective)

Also known as: DDAVP · Stimate · Minirin

A synthetic vasopressin analog with selective V2 receptor activity. FDA approved for diabetes insipidus, nocturnal enuresis, & hemophilia A/von Willebrand disease.

Typical Dose

10–40 mcg intranasal 1–2x/day (DI); 0.1–0.4 mg oral (enuresis); 0.3 mcg/kg IV (hemostasis)

Route

Intranasal, oral, subcutaneous, or IV

Cycle

Ongoing (DI); as needed (hemostasis, enuresis)

Half-life

~75 minutes (IV); 3–4 hours (intranasal)

Storage

Refrigerate nasal solution. Tablets: room temp.

Overview

Desmopressin (1-deamino-8-D-arginine vasopressin, DDAVP) is a synthetic vasopressin analog with D-arginine at position 8 & deamination of the N-terminus. These modifications eliminate V1-mediated vasoconstriction while greatly potentiating V2-mediated antidiuresis, creating a selective antidiuretic agent 10x more potent & 2–3x longer-acting than native AVP.

Clinical indications include central diabetes insipidus, primary nocturnal enuresis, & hemostasis in mild hemophilia A or von Willebrand disease (via V2-mediated vWF & factor VIII release from endothelium).

Quick Start Guide

1

Clinical use only. Intranasal, oral, or SubQ depending on indication & formulation.

Research Indications

Central diabetes insipidus

Most Effective

First-line treatment. Selective antidiuresis without vasopressor effects.

Nocturnal enuresis

Most Effective

FDA approved. Reduces nocturnal urine production.

Hemostasis (hemophilia A / vWD)

Most Effective

FDA approved. IV DDAVP releases stored vWF & factor VIII for minor procedures.

Side Effects & Safety

Common

  • Headache
  • Nasal congestion (intranasal)
  • Hyponatremia (especially in children)

Uncommon

  • Seizures (hyponatremia-related)
  • Facial flushing
  • Tachycardia

When to Stop

  • Hyponatremia or SIADH risk
  • Heart failure or renal insufficiency
  • Signs of allergic reaction

How to Reconstitute

1

Commercial product in multiple forms.

Dosing math: Clinical product only.

Quality Indicators

Good — use as normal

  • Per manufacturer

Discard immediately

  • Per manufacturer

What to Expect

Acute

Antidiuretic effect within 30–60 min of intranasal dosing. Duration 8–12 hours.

Community Insights

Self-reported. Reflects user experience, not clinical outcomes.

Verify what you have

Information on this page applies to pharmaceutical-grade peptides. Purity & identity of research-grade products vary. Certipep provides independent ESI-TOF-MS & HPLC analysis with a signed analytical report.

Submit a sample